Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens
US-12576148-B2 · Mar 17, 2026 · US
This page is not indexed by search engines while we improve data quality.
Lutteropp Michael patents
Lutteropp Michael is listed as an inventor on 16 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Lutteropp Michael |
| Total patents | 16 |
| First publication | May 26, 2016 |
| Latest publication | Mar 17, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Hematopoietic cells with a modified CD antigen for reducing side effects of cancer immunotherapy
US-12521434-B2 · Jan 13, 2026 · US
Reducing side effects of immunotherapy using genetically modified hematopoietic cells
US-12318446-B2 · Jun 3, 2025 · US
Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen
US-12246065-B2 · Mar 11, 2025 · US
Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens
US-2024316192-A1 · Sep 26, 2024 · US
Reducing side effects of immunotherapy using genetically modified hematopoietic cells
US-2024307533-A1 · Sep 19, 2024 · US
Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen
US-2024269275-A1 · Aug 15, 2024 · US
Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form
US-11883494-B2 · Jan 30, 2024 · US
Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form
US-2023248823-A1 · Aug 10, 2023 · US
Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells
US-11419935-B2 · Aug 23, 2022 · US
Recent patents
Latest publications not already listed above.
Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells
US-2021401980-A1 · Dec 30, 2021 · US
Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form
US-2021338814-A1 · Nov 4, 2021 · US
Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form
US-11033619-B2 · Jun 15, 2021 · US
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
US-10201606-B2 · Feb 12, 2019 · US
Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form
US-2018280502-A1 · Oct 4, 2018 · US
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
US-2016144026-A1 · May 26, 2016 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Miltenyi Biotec Bv & Co Kg | 13 |
| Miltenyi Biotec Gmbh | 5 |
| Mitenyi Biotec B V & Co Kg | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 16 |
| A61K2035/124 | 16 |
| A61K35/12 | 16 |
| A61K38/1774 | 16 |
| A61K39/3955 | 16 |